July 17, 2015 News by Charles Moore Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases Such As MS and IBD Summit, New Jersey based Celgene Corporation and Receptos, Inc. of San Diego, California, a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, have announced their joint signing of a definitive agreement in which Celgene will acquire Receptos. Under terms of the merger agreement,…
July 8, 2015 News by Isaura Santos 1200 People With Relapsing MS Needed For RPC1063, Avonex Clinical Trials Clinical investigatorsĀ worldwide are beginning to recruitĀ 1,200 patientsĀ with relapsing multiple sclerosisĀ for a study assessingĀ the effectiveness of two different doses of RPC1063 (Receptos, Inc.), an experimental oral therapy, and AvonexĀ® (interferon beta-1a, Biogen Inc.) in order toĀ reduce relapse rate in patients. This study, called the Sunbeam Study, is being funded by…
January 21, 2015 News by Patricia Silva, PhD Receptos Launches SUNBEAM Phase 3 Trial for Relapsing Multiple Sclerosis Therapy Biopharmaceutical companyĀ Receptos, Inc. has enrolled the first participantĀ withĀ relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapyĀ RPC1063 in patients who suffer from the disease. The company’s phase 3 RADIANCE trial, also…
December 29, 2014 News by Patricia Silva, PhD Receptos Begins RMS Patient Enrollment in SUNBEAM and RADIANCE Trials Biopharmaceutical company Receptos, Inc. is enrolling the first patient in theirĀ SUNBEAM phase 3 trial to evaluateĀ the company’s investigational therapy for the treatment ofĀ patients with relapsing multiple sclerosis (RMS) and ulcerative colitis (UC), calledĀ RPC1063. In addition, Receptos has recently started its phase 3Ā …
September 11, 2014 News by Patricia Silva, PhD Receptos to Present Data on RMS Treatment Trial at MSBoston 2014 Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…
June 10, 2014 News by admin Experimental Relapsing Multiple Sclerosis Therapy From Receptos Reveals Positive Endpoint Data in Phase 2 Results Following the promising results of prior trials, Receptos, Inc., a biopharmaceutical company engaged in the treatment of immune and metabolic diseases, announced that the Phase 2 portion of the RADIANCE trial has met the primary endpoint, a reduction in MRI brain lesion activity in patients with relapsing multiple sclerosis…